Loader

Pathways

PathWhiz ID Pathway Meta Data

PW127719

Pw127719 View Pathway
drug action

Prazepam Action Pathway

Homo sapiens
Prazepam is a benzodiazepine used to manage more severe forms of anxiety disorders. Prazepam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. It can be found under the brand names Centrac, Demetrin, and Prazene. Benzodiazepines may be habit-forming (causing mental or physical dependence), especially when taken for a long time or in high doses. Prazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation. Prazepam is a prodrug for desmethyldiazepam which is responsible for the therapeutic effects of prazepam. Some side effects of using prazepam may include drowsiness, confusion, coordination problems, and concentration and memory problems.

PW145457

Pw145457 View Pathway
drug action

Prazepam Drug Metabolism Action Pathway

Homo sapiens

PW145150

Pw145150 View Pathway
drug action

Praziquantel Drug Metabolism Action Pathway

Homo sapiens

PW126621

Pw126621 View Pathway
drug action

Prazosin Action Pathway

Homo sapiens
Prazosin is an alpha-blocker that causes a decrease in total peripheral resistance and is used to treat hypertension. This drug is indicated for the treatment of hypertension (high blood pressure). Prazosin can be given alone or given with other blood pressure-lowering drugs, including diuretics or beta-adrenergic blocking agents. Alpha-adrenergic receptors are essential for the regulation of blood pressure in humans. Two types of alpha receptors, alpha 1 and alpha 2, both play a role in regulating blood pressure. Alpha-1 receptors are postsynaptic (located after the nerve junction, or space between a nerve fiber and target tissue). In this case, the target tissue is the vascular smooth muscle. Activation of the alpha-1 receptor activates the Gq signaling cascade, which activates phospholipase C. Phospholipase C converts phosphatidylinositol 4,5-bisphosphate to diacylglycerol and inositol 1,4,5-trisphosphate (IP3). IP3 activates the IP3 receptor on the sarcoplasmic reticulum, leading to calcium influx into the cytosol from the sarcoplasmic reticulum. Calcium binds to calmodulin and activates myosin light chain kinase. Myosin light chain kinase is responsicle for phosphorylating myosin light chain. Phosphorylated myosin light chain binds to actin and causes muscle contraction. Prazosin inhibits the postsynaptic alpha-1 adrenoceptors. This inhibition blocks the vasoconstricting (narrowing) effect of catecholamines (epinephrine and norepinephrine) on the vessels, leading to peripheral blood vessel dilation. Common side effects of prazosin include dizziness, headache, drowsiness, lack of energy, weakness, palpitations and nausea.

PW144581

Pw144581 View Pathway
drug action

Prazosin Drug Metabolism Action Pathway

Homo sapiens

PW176352

Pw176352 View Pathway
metabolic

Prazosin Predicted Metabolism Pathway

Homo sapiens
Metabolites of sildenafil are predicted with biotransformer.

PW123579

Pw123579 View Pathway
disease

prctise

Homo sapiens

PW127824

Pw127824 View Pathway
drug action

Prednicarbate Action Pathway

Homo sapiens
Prednicarbate is a relatively new topical corticosteroid. It displays similar potency as hydrocortisone and has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy. Since prednicarbate is a glucocorticoid receptor agonist. By binding to the glucocorticoid receptor, it influences transcription factors AP-1 and NF-kB to block the transcription of COX-2/prostaglandin G/H synthase 2 which reduces the amount of prostanoids being produced from arachidonic acid. Prostanoids such as PGI2 and thromboxane A2 influence the effects of inflammation through vasoconstriction/dilation, pain sensitivity, and platelet aggregation. Prednicarbate also affects the promoter of annexin-1, an important inflammatory protein as it affects leukocytes and blocks phospholipase A2 which reduces the amount of arachidonic acid being cleaved from the phospholipid bilayer. Reducing the amount of arachidonic acid formed further decreases the concentrations of prostanoids mentioned calming inflammation. This molecule is administered as a topical cream or ointment.

PW145219

Pw145219 View Pathway
drug action

Prednicarbate Drug Metabolism Action Pathway

Homo sapiens

PW146927

Pw146927 View Pathway
drug action

Prednisolone acetate Drug Metabolism Action Pathway

Homo sapiens